untitled
<OAI-PMH schemaLocation=http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd>
<responseDate>2015-02-24T11:58:32Z</responseDate>
<request identifier=oai:HAL:inserm-00739799v1 verb=GetRecord metadataPrefix=oai_dc>http://api.archives-ouvertes.fr/oai/hal/</request>
<GetRecord>
<record>
<header>
<identifier>oai:HAL:inserm-00739799v1</identifier>
<datestamp>2015-02-19</datestamp>
<setSpec>type:ART</setSpec>
<setSpec>subject:sdv</setSpec>
<setSpec>collection:INSERM</setSpec>
<setSpec>collection:INED</setSpec>
<setSpec>collection:SANTE_PUB_INSERM</setSpec>
<setSpec>collection:IFR140</setSpec>
<setSpec>collection:CESP</setSpec>
<setSpec>collection:HL</setSpec>
<setSpec>collection:IRSET</setSpec>
<setSpec>collection:UNIV-RENNES1</setSpec>
<setSpec>collection:UVSQ</setSpec>
<setSpec>collection:DESIR</setSpec>
<setSpec>collection:UNIV-AG</setSpec>
<setSpec>collection:CNRS</setSpec>
<setSpec>collection:APHP</setSpec>
</header>
<metadata><dc>
<publisher>HAL CCSD</publisher>
<title lang=en>Are the same clinical risk factors relevant for incident diabetes defined by treatment, fasting plasma glucose, and HbA1c?</title>
<title lang=en>Are the same clinical risk factors relevant for incident diabetes defined by treatment, fasting plasma glucose, and HbA1c? : Risk factors: fasting glucose or HbA1c diabetes</title>
<creator>Balkau, Beverley</creator>
<creator>Soulimane, Soraya</creator>
<creator>Lange, Céline</creator>
<creator>Gautier, Alain</creator>
<creator>Tichet, Jean</creator>
<creator>Vol, Sylviane</creator>
<contributor>Centre de recherche en épidémiologie et santé des populations (CESP) ; INSERM - Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Paul Brousse - Université Paris-Sud - Paris 11 (UP11) - Université Versailles Saint-Quentin en Yvelines (UVSQ)</contributor>
<contributor>Service d'endocrinologie diabétologie et nutrition [Rennes] ; Université de Rennes 1 (UR1) - CHU Rennes - Hôpital Anne-de-Bretagne</contributor>
<contributor>Groupe d'Etude de la Reproduction Chez l'Homme et les Mammiferes (GERHM) ; INSERM - IFR140 - Université de Rennes 1 (UR1) - Institut de recherche, santé, environnement et travail [Rennes] (Irset) ; INSERM - École Nationale de la Santé Publique - Université de Rennes 1 (UR1) - Université des Antilles et de la Guyane (UAG) - Structure Fédérative de Recherche en Biologie-Santé de Rennes (Biosit) ; Université de Rennes 1 (UR1) - INSERM - CNRS - INSERM - CNRS - INSERM - École Nationale de la Santé Publique - Université des Antilles et de la Guyane (UAG) - Structure Fédérative de Recherche en Biologie-Santé de Rennes (Biosit) ; Université de Rennes 1 (UR1) - INSERM - CNRS - INSERM - CNRS</contributor>
<contributor>Institut inter Régional pour la SAnté (IRSA) ; Centre de Prévention et de Santé Publique de Tours - La Riche</contributor>
<contributor>The D.E.S.I.R. study has been supported by INSERM contracts with CNAMTS, Lilly, Novartis Pharma and Sanofi-Aventis; by INSERM (Réseaux en Santé Publique, Interactions entre les déterminants de la santé), Cohortes Santé TGIR, the Association Diabète Risque Vasculaire, the Fédération Française de Cardiologie, La Fondation de France, ALFEDIAM, ONIVINS, Société francophone du diabète , Ardix Medical, Bayer Diagnostics, Becton Dickinson, Cardionics, Merck Santé, Novo Nordisk, Pierre Fabre, Roche, Topcon.</contributor>
<description>International audience</description>
<source>Diabetes Care</source>
<publisher>American Diabetes Association</publisher>
<identifier>inserm-00739799</identifier>
<identifier>http://www.hal.inserm.fr/inserm-00739799</identifier>
<identifier>http://www.hal.inserm.fr/inserm-00739799/document</identifier>
<source>http://www.hal.inserm.fr/inserm-00739799</source>
<source>Diabetes Care, American Diabetes Association, 2011, 34 (4), pp.957-9. <10.2337/dc10-1581></source>
<identifier>DOI : 10.2337/dc10-1581</identifier>
<identifier>PUBMED : 21346181</identifier>
<language>en</language>
<subject lang=en>epidemiology</subject>
<subject lang=en>fasting plasma glucose</subject>
<subject lang=en>HbA1c</subject>
<subject lang=en>incidence</subject>
<subject lang=en>risk factors</subject>
<subject lang=en>type 2 diabetes</subject>
<subject>[SDV.SPEE] Life Sciences/Santé publique et épidémiologie</subject>
<type>Journal articles</type>
<description lang=en>OBJECTIVE: To compare incidences and risk factors for diabetes using seven definitions, with combinations of pharmacological treatment, fasting plasma glucose (FPG) ≥7.0 mmol/L, and HbA(1c) ≥6.5%. RESEARCH DESIGN AND METHODS: Participants aged 30-65 years from the Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) cohort were followed for 9 years. RESULTS: More men had incident diabetes as defined by FPG ≥7.0 mmol/L and/or treatment than by HbA(1c) ≥6.5% and/or treatment: 7.5% (140/1,867) and 5.3% (99/1,874), respectively (P < 0.009); for women incidences were similar: 3.2% (63/1,958) and 3.4% (66/1,954). Known risk factors predicted diabetes for almost all definitions. Among those with incident diabetes by FPG alone versus HbA(1c) alone, there were more men (78 vs. 35%), case patients were 8 years younger, and fewer were alcohol abstainers (12 vs. 35%) (all P < 0.005). A diabetes risk score discriminated well between those with and without incident diabetes for all definitions. CONCLUSIONS: In men, FPG definitions yielded more incident cases of diabetes than HbA(1c) definitions, in contrast with women. An FPG-derived risk score remained relevant for HbA(1c)-defined diabetes.</description>
<contributor>D.E.S.I.R. STUDY GROUP (Inter Regional Health Institute</contributor>
<contributor>IRSA</contributor>
<contributor>La Riche</contributor>
<contributor>F-37521 France)</contributor>
<date>2011-04</date>
</dc>
</metadata>
</record>
</GetRecord>
</OAI-PMH>
